The use of neuromuscular blocking agents in the ICU: Where are we now?

Critical Care Medicine

Volumn 41, Issue 5, 2013, Pages 1332-1344

  Greenberg, Steven B ^a,b   Vender, Jeffery ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

associated complications; ICU; monitoring; neuromuscular blockade; pharmacology; reversal; use

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ATRACURIUM BESILATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CARDIOVASCULAR AGENT; CISATRACURIUM; CLINDAMYCIN; CORTICOSTEROID; CYCLOSPORIN; FUROSEMIDE; IMMUNOSUPPRESSIVE AGENT; LITHIUM; MAGNESIUM; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; PHENYTOIN; POTASSIUM; PROCAINAMIDE; QUINIDINE; RANITIDINE; ROCURONIUM; SUXAMETHONIUM; TETRACYCLINE; THEOPHYLLINE; VECURONIUM;

ABDOMINAL PRESSURE; ABSENCE OF SIDE EFFECTS; ACUTE LUNG INJURY; ADRENERGIC STIMULATION; ADULT RESPIRATORY DISTRESS SYNDROME; ASTHMATIC STATE; BRADYCARDIA; CONTINUOUS INFUSION; CORNEA DISEASE; CRITICAL ILLNESS; DEEP VEIN THROMBOSIS; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; DRUG USE; GANGLION BLOCK; HISTAMINE RELEASE; HUMAN; INDUCED HYPOTHERMIA; INTENSIVE CARE UNIT; INTRAABDOMINAL HYPERTENSION; INTRACRANIAL HYPERTENSION; INTUBATION; MUSCLE CELL; MUSCLE WEAKNESS; PARALYSIS; PATIENT MONITORING; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN TEST;

CRITICAL ILLNESS; EVIDENCE-BASED MEDICINE; FEMALE; HEART ARREST; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; MALE; NEUROMUSCULAR BLOCKING AGENTS; PROGNOSIS; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK ASSESSMENT; STATUS ASTHMATICUS; TREATMENT OUTCOME;

EID: 84876524014     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31828ce07c     Document Type: Review

References (132)

1. Warr J, Thiboutot Z, Rose L, et al: Current therapeutic uses, pharmacology, and clinical considerations of neuromuscular blocking agents for critically ill adults. Ann Pharmacother 2011; 45:1116-1126
2. Merriman HM: The techniques used to sedate ventilated patients. A survey of methods used in 34 ICUs in Great Britain. Intensive Care Med 1981; 7:217-224
3. Arroliga A, Frutos-Vivar F, Hall J, et al; International Mechanical Ventilation Study Group: Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. Chest 2005; 128:496-506
4. Mehta S, Burry L, Fischer S, et al; Canadian Critical Care Trials Group: Canadian survey of the use of sedatives, analgesics, and neuromuscular blocking agents in critically ill patients. Crit Care Med 2006; 34:374-380
5. Rhoney DH, Murray K: National survey of the use of sedating drugs, neuromuscular blocking agents and reversal agents in the intensive care unit. J Intensive Care 2003; 18:139-145
6. Raoof S, Goulet K, Esan A, et al: Severe hypoxemic respiratory failure: Part 2-nonventilatory strategies. Chest 2010; 137:1437-1448
7. Arroliga AC, Thompson BT, Ancukiewicz M, et al; Acute Respiratory Distress Syndrome Network: Use of sedatives, opioids, and neuro-muscular blocking agents in patients with acute lung injury and acute respiratory distress syndrome. Crit Care Med 2008; 36:1083-1088
8. Bernard SA, Buist M: Induced hypothermia in critical care medicine: A review. Crit Care Med 2003; 31:2041-2051
9. Fagerland MJ, Erikkson LI: Current concepts in neuromuscular transmission. Br J Anaesth 2009; 103:108-114
10. Jonsson M, Dabrowski M, Gurley DA, et al: Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine. Anesthesiology 2006; 104:724-733
11. Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology 2009; 110:1244-1252
12. McManus MC: Neuromuscular blockers in surgery and intensive care, part I. Am J Health Syst Pharm 2001; 58:2287-2299
13. Miller R: Miller: Miller's Anesthesia. Second Edition. Orlando, FL, Churchill Livingstone, 2009
14. Murphy GS, Vender J: Neuromuscular blocking agents use and misuse in the intensive care unit. Crit Care Clin 2001; 17:925-942
15. Smith BS, Yogaratnam D, Levasseur-Franklin KE, et al: Introduction to drug pharmacokinetics in the critically ill patient. Chest 2012; 141:1327-1336
16. Caldwell JE, Heier T, Wright PM, et al: Temperature-dependent phar-macokinetics and pharmacodynamics of vecuronium. Anesthesiology 2000; 94:83-92
17. Smeulers NJ, Wierda JM, van den Broek L, et al: Effects of hypo-thermic cardiopulmonary bypass on the pharmacodynamics and pharmacokinetics of rocuronium. J Cardiothorac Vasc Anesth 1995; 9:700-705
18. Beaufort AM, Wierda JM, Belopavlovic M, et al: The infuence of hypothermia (surface cooling) on the time-course of action and on the pharmacokinetics of rocuronium in humans. Eur J Anaesthesiol Suppl 1995; 11:95-106
19. Atherton DP, Hunter JM: Clinical pharmacokinetics of the newer neu-romuscular blocking drugs. Clin Pharmacokinet 1999; 36:169-189
20. Magorian T, Wood P, Caldwell J, et al: The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg 1995; 80:754-759
21. Szenohradszky J, Fisher DM, Segredo V, et al: Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. Anesthesi-ology 1992; 77:899-904
22. Cooper RA, Maddineni VR, Mirakhur RK, et al: Time course of neuro-muscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isofurane anaesthesia in patients with and without renal failure. Br J Anaesth 1993; 71:222-226
23. Boyd AH, Eastwood NB, Parker CJ, et al: Comparison of the phar-macodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. Br J Anaesth 1996; 76:382-388
24. Tatro DS (Ed): Non-depolarizing muscle relaxants. In: Drug Interaction Facts. St Louis, MO, Wolters Kluwer, 2010, pp 1231-1253
25. Murphy GS, Brull SJ: Residual neuromuscular block: Lessons unlearned. Part II: Methods to reduce the risk of residual weakness. Anesth Analg 2010; 111:129-140
26. Caldwell JE: Clinical limitations of acetylcholinesterase antagonists. J Crit Care 2009; 24:21-28
27. Bevan DR, Donati F, Kopman AF: Reversal of neuromuscular blockade. Anesthesiology 1992; 77:785-805
28. Eikermann M, Zaremba S, Malhotra A, et al: Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing. Br J Anaesth 2008; 101:344-349
29. Eikermann M, Fassbender P, Malhotra A, et al: Unwarranted administration of acetylcholinesterase inhibitors can impair genioglossus and diaphragm muscle function. Anesthesiology 2007; 107:621-629
30. de Boer HD, van Egmond J, van de Pol F, et al: Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. Br J Anaesth 2006; 96:473-479
31. Fuchs-Buder T, Meistelman C, Schreiber JU: Is sugammadex economically viable for routine use. Curr Opin Anaesthesiol 2012; 25:217-220
32. Cammu G, De Kam PJ, Demeyer I, et al: Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth 2008; 100:373-379
33. Naguib M, Brull SJ: Sugammadex: A novel selective relaxant binding agent. Expert Rev Clin Pharmacol 2009; 2:37-53
34. Akha AS, Rosa J 3rd, Jahr JS, et al: Sugammadex: Cyclodextrins, development of selective binding agents, pharmacology, clinical development, and future directions. Anesthesiol Clin 2010; 28:691-708
35. McDonnell MJ, Pavy TJ, Green LK, et al: Sugammadex in the management of rocuronium induced anaphylaxis. Br J Anesth 2011; 106:199-201
36. Vender JS, Szokol J, Murphy GS, et al: Sedation, analgesia, neuro-muscular blockade in sepsis: An evidence based review. Crit Care Med 2004; 32:S554-561
37. Murphy GS, Brull SJ: Residual neuromuscular block: Lessons unlearned. Part I: Defnitions, incidence, and adverse physiologic effects of residual neuromuscular blockade. Anesth Analg 2010; 111:120-128
38. Pino RM: Neuromuscular blockade studies of critically ill patients. Intensive Care Med 2002; 28:1695-1697
39. Greenberg SB, Vender JS: Postoperative pulmonary complications. Curr Rev Clin Anesth 2011; 31:221-232
40. Sauer M, Stahn A, Soltesz S, et al: The infuence of residual neuro-muscular blockade on the incidence of critical respiratory events. A randomized prospective, placebo controlled trial. European J Anes-thesiol 2011; 28:841-848
41. Murphy GS, Szokol JW, Marymont JH, et al: Intraoperative accelero-myographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. Anesthesiology 2008; 109:389-398
42. Murphy GS, Szokol JW, Avram MJ, et al: Intraoperative accelero-myography monitoring reduces symptoms of muscle weakness and improves quality of recovery in the early postoperative period. Anes-thesiology 2011; 115:946-954
43. Puthucheary Z, Rawal J, Ratnayake G, et al: Neuromuscular blockade and skeletal muscle weakness in critically ill patients: Time to rethink the evidence? Am J Respir Crit Care Med 2012; 185:911-917
44. Forel JM, Roch A, Papazian L: Paralytics in critical care: Not always the bad guy. Curr Opin Crit Care 2009; 15:59-66
45. Khuenl-Brady KS, Reitstätter B, Schlager A, et al: Long-term administration of pancuronium and pipecuronium in the intensive care unit. Anesth Analg 1994; 78:1082-1086
46. Rudis MI, Sikora CA, Angus E, et al: A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 1997; 25:575-583
47. Strange C, Vaughan L, Franklin C, et al: Comparison of train-of-four and best clinical assessment during continuous paralysis. Am J Respir Crit Care Med 1997; 156:1556-1561
48. Baumann MH, McAlpin BW, Brown K, et al: A prospective randomized comparison of train-of-four monitoring and clinical assessment during continuous ICU cisatracurium paralysis. Chest 2004; 126:1267-1273
49. Burmester M, Mok Q: Randomised controlled trial comparing cisatra-curium and vecuronium infusions in a paediatric intensive care unit. Intensive Care Med 2005; 31:686-692
50. Stevens RD, Marshall SA, Cornblath DR, et al: A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med 2009; 37(10 Suppl):S299-S308
51. Coakley JH, Nagendran K, Yarwood GD, et al: Patterns of neurophysi-ological abnormality in prolonged critical illness. Intensive Care Med 1998; 24:801-807
52. MacFarlane IA, Rosenthal FD: Severe myopathy after status asthmati-cus. Lancet 1977; 2:615
53. Schakman O, Gilson H, Thissen JP: Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 2008; 197:1-10
54. Papazian L, Forel JM, Gacouin A, et al; ACURASYS Study Investigators: Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363:1107-1116
55. Forel JM, Roch A, Marin V, et al: Neuromuscular blocking agents decrease infammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med 2006; 34:2749-2757
56. Ballard N, Robley L, Barrett D, et al: Patients' recollections of therapeutic paralysis in the intensive care unit. Am J Crit Care 2006; 15:86-94; quiz 95
57. Loper KA, Butler S, Nessly M, et al: Paralyzed with pain: The need for education. Pain 1989; 37:315-316
58. Brook AD, Ahrens TS, Schaiff R, et al: Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med 1999; 27:2609-2615
59. Kress J P, Pohlman AS, O'Connor MF, et al: Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342:1471-1477
60. Girard TD, Kress JP, Fuchs BD, et al: Effcacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): A randomised controlled trial. Lancet 2008; 371:126-134
61. Patel SB, Kress JP: Sedation and analgesia in the mechanically ventilated patient. Am J Respir Crit Care Med 2012; 185:486-497
62. Tonner PH, Paris A, Scholz J: Monitoring consciousness in intensive care medicine. Best Pract Res Clin Anaesthesiol 2006; 20:191-200
63. Yaman F, Ozcan A, Kaymak C, et al: Assessment of correlation between bispectral index and four common sedation scales used in mechanically ventilated patients in ICU. Eur Rev Med Pharmacol Sci 2012; 16:660-666
64. Haenggi M, Ypparila-Wolters H, Buerki S, et al: Auditory event-related potentials, bispectral index, and entropy for the discrimination of different levels of sedation in intensive care unit patients. Anesth Analg 2009; 109:807-816
65. LeBlanc JM, Dasta J F, Pruchnicki MC, et al: Bispectral index values, sedation agitation scores, and plasma concentrations of lorazepam in critically ill surgical patients. Am J Crit Care 2012; 21:99-105
66. Honiden S, Siegel MD: Analytic reviews: Managing the agitated patient in the ICU: Sedation, analgesia, and neuromuscular blockade. J Intensive Care Med 2010; 25:187-204
67. Boddi M, Barbani F, Abbate R, et al: Reduction in deep venous thrombosis incidence in intensive care after a clinician education program. Thromb Hemost 2009; 8:121-128
68. Sorce LR, Hamilton SM, Gauvreau K, et al: Preventing corneal abrasions in critically ill children receiving neuromuscular blockade: A randomized controlled trial. Pediatr Crit Care Med 2009; 10:171-175
69. Mertes PM, Tajima K, Regnier-Kimmoun MA, et al: Perioperative ana-phylaxis. Med Clin North Am 2010; 94:761-789
70. Mertes PM, Laxenaire MC: Anaphylatic and anaphylactoid reactions occurring during anesthesia in France. Seventh epidemiologic survey (January 2001-December 2002). Ann Fr Anesth Reanim 2004; 23:1133-1143
71. Dewachter P, Mouton-Faivre CM, Emala CW: Anaphylaxis and anesthesia. Anesthesiology 2009; 111:1141-1150
72. Murray MJ, Cowen J, Deblock H, et al: Clinical practice guidelines for sustained neuromuscular blockade in the critically ill adult. Crit Care Med 2002; 30;142-156
73. Bailey P, Thomsen GE, Spuhler VJ, et al: Early activity is feasible and safe in respiratory failure patients. Crit Care Med 2007; 35:139-145
74. Thomsen GE, Snow GL, Rodriguez L, et al: Patients with respiratory failure increase ambulation after transfer to an intensive care unit where early activity is a priority. Crit Care Med 2008; 36:1119-1124
75. Morris PE, Goad A, Thompson C, et al: Early intensive care unit mobility therapy in the treatment of acute respiratory failure. Crit Care Med 2008; 36:2238-2243
76. Schweickert WD, Pohlman MC, Pohlman AS, et al: Early physical and occupational therapy in mechanically ventilated, critically ill patients: A randomised controlled trial. Lancet 2009; 373:1874-1882
77. Mascia MF, Koch M, Medicis JJ: Pharmacoeconomic impact of rational use guidelines on the provision of analgesia, sedation, and neuromuscular blockade in critical care. Crit Care Med 2000; 28:2300-2306
78. Chanques G, Barbotte JS, Violet S, et al: Impact of systemic evaluation of pain and agitation in an intensive care unit. Crit Care Med 2006; 34:1691-1699
79. Reynolds S F, Heffner J: Airway management of the critically ill patient: Rapid-sequence intubation. Chest 2005; 127:1397-1412
80. El-Orbany M, Connolly LA: Rapid sequence induction and intubation: Current controversy. Anesth Analg 2010; 110:1318-1325
81. Booij LH: Is succinylcholine appropriate or obsolete in the intensive care unit? Crit Care 2001; 5:245-246
82. Perry J, Lee J, Sillberg VA, et al: Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev 2008; 2:CD002788
83. Marsch SC, Steiner L, Bucher L, et al: Succinylcholine versus rocuronium for rapid sequence intubation in intensive care: A prospective, randomized trial. Crit Care 2011; 15:R199-R208
84. Wilcox SR, Bittner EA, Elmer J, et al: Neuromuscular blocking agent administration for emergent tracheal intubation is associated with decreased prevalence of procedure-related complications. Crit Care Med 2012; 40:1808-1813
85. Rubenfeld GD, Herridge MS: Epidemiology and outcomes of acute lung injury. Chest 2007; 131:554-562
86. Zambon M, Vincent JL: Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest 2008; 133:1120-1127
87. Bennett S, Hurford WE: When should sedation or neuromuscu-lar blockade be used during mechanical ventilation? Respir Care 2011; 56:168-176
88. Bishop MJ: Hemodynamic and gas exchange effects of pancuronium bromide in sedated patients with respiratory failure. Anesthesiology 1984; 60:369-371
89. Conti G, Vilardi V, Rocco M, et al: Paralysis has no effect on chest wall and respiratory system mechanics of mechanically ventilated, sedated patients. Intensive Care Med 1995; 21:808-812
90. Freebairn RC, Derrick J, Gomersall CD, et al: Oxygen delivery, oxygen consumption, and gastric intramucosal pH are not improved by a computer-controlled, closed-loop, vecuronium infusion in severe sepsis and septic shock. Crit Care Med 1997; 25:72-77
91. Gainnier M, Roch A, Forel JM, et al: Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med 2004; 32:113-119
92. Lagneau F, D'honneur G, Plaud B, et al: A comparison of two depths of prolonged neuromuscular blockade induced by cisatracurium in mechanically ventilated critically ill patients. Intensive Care Med 2002; 28:1735-1741
93. Appleton R, Kinsella J: Intensive care unit-acquired weakness. Con-tin Educ Anaesth Crit Care Pain 2012; 12:62-66
94. Leatherman JW, Fluegel WL, David WS, et al: Muscle weakness in mechanically ventilated patients with severe asthma. Am J Respir Crit Care Med 1996; 153:1686-1690
95. Goh AY, Chan PW: Acute myopathy after status asthmaticus: Steroids, myorelaxants or carbon dioxide? Respirology 1999; 4:97-99
96. Adnet F, Dhissi G, Borron SW, et al: Complication profles of adult asthmatics requiring paralysis during mechanical ventilation. Intensive Care Med 2001; 27:1729-1736
97. Kesler SM, Sprenkle MD, David WS, et al: Severe weakness complicating status asthmaticus despite minimal duration of neuromus-cular paralysis. Intensive Care Med 2009; 35:157-160
98. Oddo M, Feihl F, Schaller MD, et al: Management of mechanical ventilation in acute severe asthma: Practical aspects. Intensive Care Med 2006; 32:501-510
99. Ohlinger MJ, Rhoney DH: Neuromuscular blocking agents in the neurosurgical intensive care unit. Surg Neurol 1998; 49:217-221
100. Hsiang JK, Chesnut RM, Crisp CB, et al: Early, routine paralysis for intracranial pressure control in severe head injury: Is it necessary? Crit Care Med 1994; 22:1471-1476
101. Schramm WM, Jesenko R, Bartunek A, et al: Effects of cisatra-curium on cerebral and cardiovascular hemodynamics in patients with severe brain injury. Acta Anaesthesiol Scand 1997; 41: 1319-1323
102. Prielipp RC, Robinson JC, Wilson JA, et al: Dose response, recovery, and cost of doxacurium as a continuous infusion in neu-rosurgical intensive care unit patients. Crit Care Med 1997; 25: 1236-1241
103. Schramm WM, Papousek A, Michalek-Sauberer A, et al: The cerebral and cardiovascular effects of cisatracurium and atracurium in neurosurgical patients. Anesth Analg 1998; 86:123-127
104. Kerr ME, Sereika SM, Orndoff P, et al: Effect of neuromuscular blockers and opiates on the cerebrovascular response to endotra-cheal suctioning in adults with severe head injuries. Am J Crit Care 1998; 7:205-217
105. Juul N, Morris GF, Marshall SB, et al: Neuromuscular blocking agents in neurointensive care. Acta Neurochir Suppl 2000; 76:467-470
106. Rangel-Castillo L, Gopinath S, Robertson CS: Management of intracranial hypertension. Neurol Clin 2008; 26:521-541
107. Brain Trauma Foundation, American Association of Neurological Surgeons (AANS), Congress of Neurological Surgeons (CNS), AANS/CNS Joint Section on Neurotrauma and Critical Care: Guidelines for the management of traumatic brain injury. J Neu-rotrauma 2007; 24:S71-S76
108. Cheatham ML: Intraabdominal pressure monitoring during fuid resuscitation. Curr Opin Crit Care 2008; 14:327-333
109. Malbrain ML, CheathamML, Kirkpatrick A, et al: Results from the conference of experts on intra-abdominal hypertension and abdominal compartment syndrome. Part I: Defnitions. Intensive Care Med 2006; 32:1722-1732
110. Cheatham ML, Malbrain MLNG, Kirkpatrick A, et al: Results from the conference of experts on intra-abdominal hypertension and abdominal compartment syndrome. Part II: Recommendations. Intensive Care Med 2007; 33:951-962
111. De Waele J, Delaet I, Hoste E, et al. The effect of neuromuscular blockers on intraabdominal pressure. Crit Care Med 2006; 34:A70
112. Mertens zur Borg IR, Verbrugge SJ, Kolkman KA: Anesthetic considerations in abdominal compartment syndrome. In: Abdominal Compartment Syndrome. Ivatury RR, Cheatham ML, Malbrain MLNG, et al (Eds). Landes Biomedical, Georgetown, 2006, pp 254-265
113. An G, West MA: Abdominal compartment syndrome: A concise clinical review. Crit Care Med 2008; 36:1304-1310
114. Davies J, Aghahoseini A, Crawford J, et al: To close or not to close? Treatment of abdominal compartment syndrome by neuromuscular blockade without laparostomy. Ann R Coll Surg Engl 2010; 92:W8-W9
115. Luckianow GM, Ellis M, Governale D, et al: Abdominal compartment syndrome: Risk factors, diagnosis, and current therapy. Crit Care Res Pract 2012; 908169:1-8
116. Bernard SA, Gray TW, Buist MD, et al: Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002; 346:557-563
117. The Hypothermia After Cardiac Arrest Study Group: Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002; 346:549-556
118. Polderman KH: Application of therapeutic hypothermia in the ICU: Opportunities and pitfalls of a promising treatment modality. Part 1: Indications and evidence. Intensive Care Med 2004; 30: 556-575
119. Holzer M, Bernard SA, Hachimi-Idrissi S, et al; Collaborative Group on Induced Hypothermia for Neuroprotection After Cardiac Arrest: Hypothermia for neuroprotection after cardiac arrest: Systematic review and individual patient data meta-analysis. Crit Care Med 2005; 33:414-418
120. Ramani R: Hypothermia for brain protection and resuscitation. Curr Opin Anaesthesiol 2006; 19:487-491
121. Alzaga AG, Cerdan M, Varon J: Therapeutic hypothermia. Resuscitation 2006; 70:369-380
122. Rincon F, Mayer SA: Therapeutic hypothermia for brain injury after cardiac arrest. Semin Neurol 2006; 26:387-395
123. Howes D, Green R, Gray S, et al; Canadian Association of Emergency Physicians: Evidence for the use of hypothermia after cardiac arrest. CJEM 2006; 8:109-115
124. Cheung KW, Green RS, Magee KD: Systematic review of randomized controlled trials of therapeutic hypothermia as a neuroprotec-tant in post cardiac arrest patients. CJEM 2006; 8:329-337
125. Holzer M, Behringer W: Therapeutic hypothermia after cardiac arrest and myocardial infarction. Best Pract Res Clin Anaesthesiol 2008; 22:711-728
126. Schneider A, Böttiger BW, Popp E: Cerebral resuscitation after car-diocirculatory arrest. Anesth Analg 2009; 108:971-979
127. Chamorro C, Borrallo JM, Romera MA, et al: Anesthesia and analgesia protocol during therapeutic hypothermia after cardiac arrest: A systematic review. Anesth Analg 2010; 110:1328-1335
128. Heier T, Caldwell JE: Impact of hypothermia on the response to neu-romuscular blocking drugs. Anesthesiology 2006; 104:1070-1080
129. Prielipp RC, Coursin DB: Applied pharmacology of common neu-romuscular blocking agents in critical care. New Horiz 1994; 2:34-47
130. Behbehani NA, Al-Mane F, D'yachkova Y, et al: Myopathy following mechanical ventilation for severe acute asthma: The role of muscle relaxants and corticosteroids. Chest 1999; 115:1627-1631
131. Griffn D, Fairman N, Coursin D, et al: Acute myopathy during treatment of status asthmaticus with corticosteroids and steroidal muscle relaxants. Chest 1992; 102:510-514
132. Cheatham ML, Safcsak K: Is the evolving management of intra-abdominal hypertension and abdominal compartment syndrome improving survival? Crit Care Med 2010; 38:402-407